Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it “frustrating” that despite the favorable Zantac settlement, robust performance of GSK’s Specialty unit, and pipeline successes, the shares “continue to languish.” While GSK’s fundamental value remains compelling, overhangs for the company’s Arexvy and Shingrix vaccines, “more subdued” 2025 growth, and few near-term catalysts to “rebuild belief” suggests the stock’s value disconnect may persist, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GSK:
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Cigna drops pursuit of Humana: Morning Buzz
- GSK to quit lobbying group BIO, STAT reports
- Ex-Dividend Date Nearing for These 10 Stocks – Week of November 11, 2024
- GSK price target lowered to 1,450 GBp from 1,550 GBp at Barclays
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
